Virginia Commonwealth University
The primary objective of this pilot study is to evaluate the feasibility and acceptability of a clinical trial protocol investigating 10 mg/day empagliflozin in breast cancer patients receiving anthracycline-based chemotherapy.
This is a prospective, single-arm pilot study designed to evaluate the feasibility of treating breast cancer patients receiving potentially cardiotoxic chemotherapy with empagliflozin 10 mg daily to prevent heart failure progression. Participants will undergo study assessments at baseline and again approximately 3 months later. The study will collect clinical, imaging, functional, and biomarker data to inform the design of future, larger clinical trials
Inclusion Criteria: * Stage I-III breast cancer (including inflammatory and newly diagnosed, or locally recurrent but not metastatic breast cancer being treated with curative intent) * 18-85 years old * Scheduled to receive anthracycline based chemotherapy with or without estrogen antagonist aromatase inhibitors (anastrozole \[Arimidex\], letrozole \[Femara\], exemestane \[Aromasin\]). * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * Able to walk at least 2 blocks without chest pain, dyspnea or fainting * Participants in other ongoing clinical trials are eligible for thi…
Empagliflozin 10 milligrams (mg) taken by mouth once daily.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.